Ser63
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser63  -  WT1 iso7 (human)

Site Information
ERLQGRRsRGAsGsE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1871128700

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 1 ) , immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 1 ) , colorectal carcinoma ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 ) , non-small cell large cell lung carcinoma ( 1 ) , non-small cell squamous cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 1 )
Kinases, in vitro:
GSK3B (human) ( 1 )
Treatments:
lithium ( 1 ) , LY294002 ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on WT1 iso7:
molecular association, regulation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 1 ) , cell growth, inhibited ( 1 ) , transcription, inhibited ( 1 )
Induce interaction with:
FBXW8 (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
lung cancer ( 1 )

References 

1

Yoshitomi H, et al. (2020) GSK3β-mediated expression of CUG-translated WT1 is critical for tumor progression. Cancer Res
33184107   Curated Info